-
Publication Venue For
-
Fatigue in older cancer patients: etiology, assessment, and treatment..
35:633-642.
2008
-
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B..
35:470-483.
2008
-
Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer..
35:251-261.
2008
-
Salivary gland malignancies: the role for chemotherapy and molecular targeted agents..
35:309-319.
2008
-
Surgical therapy of cutaneous melanoma..
34:270-280.
2007
-
Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events..
33:S26-S34.
2006
-
Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice..
33:S35-S40.
2006
-
Myelotoxicity from chemotherapy..
33:74-85.
2006
-
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer..
32:S35-S41.
2005
-
Combined modality treatment for rectal cancer..
32:103-112.
2005
-
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer..
32:61-68.
2005
-
Descriptive epidemiology and risk factors for head and neck cancer..
31:726-733.
2004
-
The importance of chemotherapy dose intensity in lung cancer..
31:25-31.
2004
-
Breast cancer in older patients..
31:234-248.
2004
-
Geriatric assessment and comorbidity..
31:149-159.
2004
-
Molecular classification and molecular genetics of human lung cancers..
31:4-19.
2004
-
Balancing the benefits and costs of colony-stimulating factors: a current perspective..
30:10-17.
2003
-
Combined modality therapy for rectal and colon cancer..
30:101-112.
2003
-
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia..
30:24-30.
2003
-
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer..
30:39-50.
2003
-
Cost-effectiveness considerations in the treatment of essential thrombocythemia..
29:28-32.
2002
-
The role of imaging in malignant pleural mesothelioma..
29:26-35.
2002
-
Past and present treatment of pancreatic adenocarcinoma: Chemotherapy as a standard treatment modality.
29:2-8.
2002
-
Platelet-derived growth factor receptors: a therapeutic target in solid tumors..
28:27-33.
2001
-
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report..
28:40-44.
2001
-
Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate..
28:8-15.
2001
-
Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index..
28:25-33.
2001
-
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report.
28:40-44.
2001
-
Platelet-derived growth factor receptors: A therapeutic target in solid tumors.
28:27-33.
2001
-
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
27:35-40.
2000
-
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
27:S35-S40.
2000
-
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis..
27:35-40.
2000
-
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780.
26:39-44.
1999
-
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780.
26:39-44.
1999
-
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780..
26:39-44.
1999
-
Imaging lung cancer.
26:21-26.
1999
-
Imaging lung cancer..
26:21-26.
1999
-
Imaging lung cancer.
26:21-26.
1999
-
Hematopoietic growth factors in the reduction of chemotherapeutic toxicity..
25:552-561.
1998
-
Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma..
25:447-460.
1998
-
Exercise and the treatment of wasting: aging and human immunodeficiency virus infection..
25:112-122.
1998
-
Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia..
25:80-97.
1998
-
Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results..
24:S19-57-S19-61.
1997
-
Hyperthermic treatment of malignant diseases: current status and a view toward the future..
24:616-625.
1997
-
Intraoperative irradiation: current and future status..
24:715-731.
1997
-
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer.
24.
1997
-
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer..
24:S12-130-S12-134.
1997
-
Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer.
24.
1997
-
Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer..
24:S8-42-S8-45.
1997
-
Phase I studies with the novel nucleoside analog gemcitabine..
23:25-31.
1996
-
Epirubicin and ifosfamide in metastatic breast cancer.
23:28-33.
1996
-
Epirubicin and ifosfamide in metastatic breast cancer..
23:28-33.
1996
-
Update on the role of vinorelbine in the treatment of non-small cell lung cancer: Introduction.
23:1.
1996
-
Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1)..
23:22-24.
1996
-
Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2)..
23:53-55.
1996
-
Update: vinorelbine (navelbine) in non-small cell lung cancer..
23:2-7.
1996
-
Phase I studies with the novel nucleoside analog gemcitabine.
23:25-31.
1996
-
A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: A study of the North Central Cancer Treatment Group.
22:75-77.
1995
-
A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group..
22:75-77.
1995
-
The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy..
22:18-22.
1995
-
Geriatric principles of treatment applied to medical oncology: an overview..
22:1-2.
1995
-
Geriatric principles of treatment applied to medical oncology: An overview.
22:1-2.
1995
-
Vinorelbine (Navelbine) in non-small cell lung cancer: future directions..
21:85-88.
1994
-
Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor..
21:73-78.
1994
-
Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience..
21:60-65.
1994
-
Immunobiology of malignant astrocytomas..
21:149-161.
1994
-
Nonoperative management of non-small cell lung cancer: The current Cancer and Leukemia Group B experience.
21:60-65.
1994
-
The biology of unknown primary tumors..
20:238-243.
1993
-
Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy..
19:33-37.
1992
-
alpha-Interferon and 5-fluorouracil: possible mechanisms of antitumor action..
18:71-76.
1991
-
Chemotherapy-induced emergencies..
16:572-578.
1989
-
Identification and assessment of prognostic factors..
15:462-471.
1988
-
Studies of ara-C metabolism in acute leukemia..
14:182-191.
1987
-
Immunobiology of human gliomas..
13:94-109.
1986
-
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
11:41-46.
1984
-
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
2002
-
Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
2002
-
Evolving concepts in chemotherapy and surgery for bilio-pancreatic cancer: Introduction
2002